Neuropeptides: review time and acceptance speed

ISSN 0143-4179 · ISSN 1532-2785 · Elsevier BV · Neuroscience

Half of the articles Neuropeptides accepted in 2024 were accepted within 63 days of submission (n = 54); the middle half took 49–97 days.

Submission → acceptance (2024)
63 days median
middle half 49–97 · n = 54
Acceptance → online
2 days median
middle half 2–4 · n = 54
Change since 2022
Faster than 2022: the median fell from 115 to 63 days (90% CI -82 to -22 days).
Open access · fees
OA status not determined · ≈$3,530

Accepted articles only · dates deposited by the publisher in PubMed · data as of Sep 15, 2026

Plan submissions to a deadline — free

How long does Neuropeptides take to accept a paper?

days0601201802402020: middle half 89–198 days1342020n=552021: middle half 86–158 days1282021n=582022: middle half 70–171 days1152022n=512024: middle half 49–97 days632024n=54
Line = median; shaded box = middle half of articles (25th–75th percentile). Year of acceptance.
Days from submission to acceptance, by year of acceptance
YearArticles (n)25th pctMedian75th pct90th pctAccepted <14 daysHave a revised date
2024544963970.0%100%
202251701151710.0%100%
202158861281580.0%97%
202055891341980.0%100%

Distribution in 2024

0–29 days: 4% (2 articles)030–59 days: 41% (22 articles)3060–89 days: 24% (13 articles)6090–119 days: 15% (8 articles)90120–149 days: 9% (5 articles)120150–179 days: 6% (3 articles)150180–209 days: 0% (0 articles)180210–239 days: 2% (1 articles)210240–269 days: 0% (0 articles)240270–299 days: 0% (0 articles)270300–329 days: 0% (0 articles)300330–359 days: 0% (0 articles)330360+ days: 0% (0 articles)360+days from submission to acceptance (30-day bins)
Show as a table
DaysArticlesShare
0–2923.7%
30–592240.7%
60–891324.1%
90–119814.8%
120–14959.3%
150–17935.6%
180–20900.0%
210–23911.9%
240–26900.0%
270–29900.0%
300–32900.0%
330–35900.0%
360+00.0%

From acceptance to online publication

After acceptance, half of the 2024 articles appeared online within 2 days (middle half 2–4 days, n = 54).

From submission to online publication, the median was 67 days (middle half 50–100 days, n = 54).

Read these numbers carefully

  • These times describe articles the journal accepted. Rejected manuscripts never appear in public data, so they cannot tell you how long a rejection takes.
  • Dates are the ones the publisher deposited with PubMed. Some publishers record the date a revised manuscript arrived as the submission date, which makes review look faster.
  • Invited articles and special issues can move faster than regular submissions.

Open access status and publishing fees

Subscription or hybrid (not determined). Listed APC: about $3,530 (as reported by OpenAlex).

No institutional payments for this journal are recorded in OpenAPC.

Many journals waive or reduce fees for authors from eligible countries or institutions with publishing agreements — check with the journal and your library.

Integrity and indexing signals

Facts from public records, shown without judgement. See the methodology for why each can be worth a closer look.

Listed in DOAJNo
Articles indexed for MEDLINE in 2024Yes
Retractions1 retracted article among 252 added to PubMed in 2021–2025 (3.97 per 1,000), per the Retraction Watch Database.
Accepted within 14 days of submission0.0% of 2024 articles
Publication volume54 articles added to PubMed in 2024.

Topics and scope

Neuroscience journalsCellular and Molecular Neuroscience journals

Similar journals — faster or cheaper, side by side

Journals publishing on the most similar topics (OpenAlex), ordered by similarity. Only 2024 figures are compared with the 2024 median of Neuropeptides, 63 days.

Paid APC medianDOAJMEDLINE
Peptides73 (2024, n = 101)≈$3,710NoYes
Life Sciences90 (2024, n = 723)≈$3,810NoYes
European Journal of Pharmacology116 (2024, n = 713)≈$3,230NoYes
Trends in Pharmacological Sciences39 (2024, n = 108)≈$7,030NoYes
Journal of Pharmacology and Experimental Therapeutics105 (2024, n = 160)≈$3,750NoYes
Molecular Pharmacology98 (2024, n = 58)≈$3,600NoYes
British Journal of Pharmacology175 (2024, n = 301)≈$4,780NoYes
Pharmacological Research86 (2024, n = 411)$4,510$4,105 (6 payments)YesYes

Frequently asked questions

How long does Neuropeptides take to accept a paper?

Half of the articles Neuropeptides accepted in 2024 were accepted within 63 days of submission (n = 54); the middle half took 49–97 days. Based on dates in PubMed for accepted articles only.

How long after acceptance are Neuropeptides articles published online?

Half of the articles accepted in 2024 appeared online within 2 days of acceptance (n = 54).

Does Neuropeptides charge an article processing charge (APC)?

Listed APC: about $3,530 (as reported by OpenAlex).

Sources and method

Journal identity: ISSN-L 0143-4179; NLM ID 8103156; OpenAlex record. Speed figures use 54 articles accepted in 2024 with valid dates; excluded records for that year: none.

Spotted a problem with this journal's data, or are you the publisher? Report a correction or email rafiq@gradsummit.com. Verified errors are corrected within five business days.

Get the free Journal Submission Go/No-Go Checklist

The pre-submission checks from Write and Publish a Scientific Paper: journal fit, formatting, cover letter and reviewer suggestions. We’ll email you the download link.

One email with your download, then occasional research tips. One-click unsubscribe, anytime. We never sell your data.

Get Write and Publish a Scientific Paper

Data sources. Submission, acceptance and publication dates: Courtesy of the U.S. National Library of Medicine (PubMed, entries through Sep 15, 2026). NLM does not endorse Journal Clock, and these figures may not reflect the most current PubMed data. Journal fees and open-access listing: DOAJ (CC0, retrieved Sep 16, 2026). Fees paid by institutions: OpenAPC (Open Database License, retrieved Sep 16, 2026). Retractions: Retraction Watch Database via Crossref (retrieved Sep 16, 2026). Journal identifiers and topics: OpenAlex (CC0). Currency conversion: ECB reference rates (Sep 15, 2026). How these numbers are calculated · For organisations.